Valuation: Grifols, S.A.

Market Cap 5.88B 6.81B 5.52B 5.02B 9.45B 651B 9.58B 64.67B 25.34B 326B 25.57B 25.02B 1,085B P/E 2026 *
12.5x
P/E 2027 * 9.56x
Enterprise Value 14.33B 16.59B 13.44B 12.24B 23.02B 1,587B 23.34B 158B 61.74B 795B 62.3B 60.95B 2,644B EV / Sales 2026 *
1.87x
EV / Sales 2027 * 1.72x
Free-Float
79.65%
Yield 2026 *
2.81%
Yield 2027 * 3.07%
1 day-2.96%
1 week-2.24%
Current month-5.76%
1 month+5.65%
3 months+0.77%
6 months-15.48%
Current year-13.82%
1 week 6.55
Extreme 6.55
6.75
1 month 6.15
Extreme 6.15
7.1
Current year 5.95
Extreme 5.95
8.35
1 year 5.95
Extreme 5.95
8.9
3 years 4.78
Extreme 4.78
10.6
5 years 4.78
Extreme 4.78
13.1
10 years 4.78
Extreme 4.78
23.4
Manager TitleAgeSince
Chief Executive Officer 58 2024-03-31
Director of Finance/CFO 49 2024-09-15
Compliance Officer 54 2013-12-31
Director TitleAgeSince
Chairman 76 2010-01-24
Director/Board Member 70 2000-04-12
Director/Board Member 62 2015-05-23
Change 5-day change 1-year change 3-year change Capi.($)
-2.96%-2.24% - - 6.86B
+0.30%-0.26%+38.86%+1.15% 80.23B
-1.02%-1.34%-2.54%+30.42% 50.64B
+1.46%-4.31%+11.90%+164.55% 46.87B
+15.30%+12.10%-42.85%-42.69% 46.34B
-0.32%+0.98%+50.90%-20.02% 31B
+1.80%+7.77%+130.05%-39.33% 25.28B
+2.78%+1.60%+42.08%+92.34% 24.36B
-0.05%-0.26%-6.48%+203.02% 20.81B
+3.95%+1.64%+67.20%+120.52% 16.08B
Average +2.12%+0.42%+32.13%+56.66% 37.96B
Weighted average by Cap. +2.56%+0.17%+24.58%+41.46%

Financials

2026 *2027 *
Net sales 7.66B 8.87B 7.18B 6.54B 12.3B 848B 12.47B 84.19B 32.99B 425B 33.29B 32.57B 1,413B 8.13B 9.42B 7.63B 6.95B 13.07B 901B 13.25B 89.46B 35.06B 451B 35.38B 34.61B 1,501B
Net income 536M 620M 502M 458M 861M 59.32B 872M 5.89B 2.31B 29.72B 2.33B 2.28B 98.86B 699M 810M 656M 598M 1.12B 77.45B 1.14B 7.69B 3.01B 38.8B 3.04B 2.98B 129B
Net Debt 8.45B 9.78B 7.92B 7.22B 13.57B 935B 13.76B 92.88B 36.4B 469B 36.73B 35.93B 1,559B 8.1B 9.39B 7.6B 6.92B 13.02B 898B 13.2B 89.13B 34.93B 450B 35.24B 34.48B 1,496B
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
25,258
Date Price Change
26-08-17 €6.550 -2.96%
26-08-14 €6.750 0.00%
26-08-13 €6.750 0.00%
26-08-12 €6.750 0.00%
26-08-11 €6.750 +0.75%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
9.814EUR
Average target price
14.53EUR
Spread / Average Target
+48.09%

Quarterly revenue - Rate of surprise